Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANVAS cardiovascular outcomes study of canagliflozin in adults with type 2 diabetes mellitus
NL-OMON36405Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of canagliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Major adverse cardiovascular events and Safety and tolerability. Started Jan 2010; status: active, not recruiting.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON36405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36405.